+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
AARTIPHARM

Aarti Pharmalabs Share Price

₹855.50 -23.55 (-2.68%)
46.24% Gain from 52W Low

09 Oct, 2026 3:59 PM (IST)

Aarti Pharmalabs live price: ₹855.50. It opened at ₹881 vs previous close ₹879; intraday high/low: ₹892/₹850. The 50 & 200 DMA stand at ₹849.60/₹769.90.

Aarti Pharmalabs Performance

  • Today's Low
  • ₹850
  • Today's High
  • ₹892
  • 52 Week Low
  • ₹585
  • 52 Week High
  • ₹1,002
  • Open Price₹881
  • Previous Close₹879
  • Volume489,421
  • 50 DMA₹849.60
  • 100 DMA₹799.90
  • 200 DMA₹769.90

Aarti Pharmalabs Chart

Investment Returns

  • Over 1 Month + 3.6%
  • Over 3 Month + 20.59%
  • Over 6 Month + 24.16%
  • Over 1 Year + 2.9%

Smart Investing Starts Here Start SIP with Aarti Pharmalabs for Steady Growth!

Invest Now

Aarti Pharmalabs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 36.4
  • PEG Ratio
  • -1.8
  • Market Cap Cr
  • 7,758
  • P/B Ratio
  • 3.5
  • Average True Range
  • 47.7
  • EPS
  • 23.5
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 23.6
  • RSI
  • 44.98
  • MFI
  • 77.1

Latest Stock News Updates

Aarti Pharmalabs Ltd - 543748 - Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended September 30, 2026

Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended September 30, 2026

Aarti Pharmalabs Ltd - 543748 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended September 30, 2026.

Aarti Pharmalabs Ltd - 543748 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Please find enclosed

Aarti Pharmalabs Financials

Aarti Pharmalabs Technicals

EMA & SMA

Current Price
₹855.50
-23.55 (-2.68%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹901.20
  • 50 Day
  • ₹849.60
  • 100 Day
  • ₹799.90
  • 200 Day
  • ₹769.90

Resistance and Support

865.83 Pivot Speed
  • R3 923.70
  • R2 907.80
  • R1 881.70
  • S1 839.70
  • S2 823.80
  • S3 797.70

Aarti Pharmalabs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-10-28 Quarterly Results
2026-08-07 Quarterly Results
2026-05-25 Audited Results & Final Dividend (Revised)
2026-02-09 Quarterly Results & Interim Dividend
2025-11-09 Quarterly Results
Date Purpose Remarks
2026-09-15 FINAL Rs.2.00 per share(40%)Final Dividend
2026-02-16 INTERIM Rs.1.50 per share(30%)Interim Dividend
2025-09-15 FINAL Rs.2.50 per share(50%)Final Dividend
2025-02-14 INTERIM Rs.2.50 per share(50%)Interim Dividend
2024-07-31 FINAL Rs.1.00 per share(20%)Final Dividend
View Aarti Pharmalabs Dividend History Arrow

Aarti Pharmalabs Shareholding Pattern

42.86%
41.74%
8.17%
6.44%
0.79%

About Aarti Pharmalabs

Aarti Pharmalabs engaged in the manufacture of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates and Xanthine Derivatives in India. View More
  • NSE Symbol
  • AARTIPHARM
  • BSE Symbol
  • 543748
  • ISIN
  • INE0LRU01027

Similar Stocks to Aarti Pharmalabs

Aarti Pharmalabs FAQs

Aarti Pharmalabs share price is ₹855 As on 11 October, 2026 | 11:57

The Market Cap of Aarti Pharmalabs is ₹7757.7 Cr As on 11 October, 2026 | 11:57

The P/E ratio of Aarti Pharmalabs is 36.4 As on 11 October, 2026 | 11:57

The PB ratio of Aarti Pharmalabs is 3.5 As on 11 October, 2026 | 11:57

The 52 week High & Low of Aarti Pharmalabs is ₹1002.4/₹585 respectively As on 11 October, 2026 | 11:57

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23